Terminal
Infiniti Feed

Viking Therapeutics acquisition odds slip to 10.0% on Polymarket

PredictionBubbles' finance board, on its Nov. 1 live read at 10:56 UTC across 182 open finance markets, lists the Viking Therapeutics acquisition contract at 10.0%, down…

Polymarket’s contract on whether Viking Therapeutics will be acquired before 2027 stood at 10.0%, down 1.0 points, according to PredictionBubbles. Reported trading volume was $1.7M.

Acquisition contract in focus

The contract concerns an acquisition before 2027. Its quoted probability places that outcome well below an even chance, though the supplied material does not identify what drove the decline.

PredictionBubbles’ finance board listed the contract in its Nov. 1 live read at 10:56 UTC, covering 182 open finance markets.

The supplied item carries a publication timestamp of Nov 1, 2026 · 5:54 AM ET. Only a truncated summary and headline were provided, with no source links or additional acquisition reporting.

What it means for prediction markets

  • Low implied probability: The 10.0% price reflects market pricing for an acquisition before 2027, not confirmation of corporate plans.
  • Weaker pricing: The reported 1.0-point decline indicates a lower quoted probability; the material does not specify the comparison period.
  • Limited context: The $1.7M traded figure provides volume context, but the supplied information does not establish current liquidity or explain the price move.
PredictionMarketsPolymarketInfiniti MarketsInfiniti Signals

Sources & attribution

Published
  1. Source 1
    Polymarketpolymarket.com
    Publisher
    https://polymarket.com
    Source URL
    The feed did not publish this story's article address.
  2. Source 2
    PredictionBubblespredictionbubbles.com
    Publisher
    https://predictionbubbles.com
    Source URL
    The feed did not publish this story's article address.

Full attribution under the Digital Millennium Copyright Act (DMCA), 17 U.S.C. § 512: this article is an original report by Infiniti Intelligence that summarizes the reporting of the publishers named above, links to their original work, and reproduces no protected expression beyond brief factual reference and in-line attribution (“according to Polymarket”). All rights in the underlying reporting remain with the publishers listed; nothing here implies endorsement by or affiliation with them. Rights holders may request correction, update or removal through the contact address published at infiniti.w3ai.io.

Related